Test Code HbsaQnt Hepatitis B Surface Antibody, Quant/Qual
Useful For
The Atellica® IM Anti-Hepatitis B surface Antigen 2 (aHBs2) assay is an in vitro diagnostic immunoassay for the qualitative and quantitative determination of total antibodies to hepatitis B surface antigen in human adult, adolescent, and pediatric serum or plasma (EDTA, lithium heparinized, or sodium heparinized) and neonatal samples using the Atellica® IM Analyzer. The assay results may be used as an aid in the determination of susceptibility to hepatitis B virus (HBV) infection in individuals prior to or following HBV vaccination or where vaccination status is unknown. Assay results may be used with other HBV serological markers for the laboratory diagnosis of HBV disease associated with HBV infection. A reactive assay result will allow a differential diagnosis in individuals displaying signs and symptoms of hepatitis in whom etiology is unknown.
Patient Preparation
No special patient preparation required
Collection Method
Venous collection
Minimum Volume
1 mL
Preferred Specimen
Serum
Acceptable Specimens
Serum:
- Gold Top SST
- Red Top
Plasma:
- Purple or Pink Top(K2/K3 EDTA)
- Light Green (Lithium heparin)
- Dark Green (Sodium heparin)
Reference or Target Ranges
Nonreactive
Reportable Units
mIU/mL
Critical Value
Not defined for this assay
Reasons for Rejection
Hemolysis Threshold | 500 mg/dL |
Icterus Threshold | 40 mg/dL |
Lipemia Threshold | 1000 mg/dL |
Other | QNS, contaminated, improperly Labeled, improper specimen type |
Specimen Stability
Ambient | 24 hours |
Refrigerated (4°C to 8°C) | Serum & Plasma: 4 days |
Frozen(-40°C to 0°C) | 3 months |
Performance Information
Days and Time Performed | 24/7 |
Expected Turn Around Time | Routine: 4 hours |
Stat Availability | No |
Performing Bench | UH Chemistry |
Methodology/Method Description | Siemens Atellica – Direct Chemiluminescent Immunoassay |
Special Handling
Samples that have been frozen or contain precipitates should be centrifuged prior to performing the assay.
Additional Information/Important Notes
Result Clarification
Nonreactive: Samples with an initial value <8.0 mIU/mL. Anti-HBS is <10.0 mIU/mL and the patient is considered not to have protective immunity to Hepatitis B Virus.
Reactive: Samples with an initial value ≥ 12.0 mIU/mL. Anti-HBs is detected at ≥ 10.0 mIU/mL and the patient is considered to have protective immunity to Hepatitis B Virus infection.
CPT Codes
86317